Key terms
About AMLX
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AMLX news
Apr 16
5:32am ET
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
Apr 12
1:39am ET
Amylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial Results
Apr 11
6:31am ET
Amylyx price target lowered to $3 from $4 at Baird
Apr 10
1:15pm ET
Amylyx to hold a conference call
Apr 08
6:16am ET
Optimistic Outlook for Amylyx Pharmaceuticals Inc with AMX0035’s Potential in Rare Diseases
Apr 08
4:25am ET
Amylyx Pharmaceuticals Shifts Focus: Hold Recommendation Amidst R&D Pivot and Revenue Impact
Apr 05
4:57am ET
Amylyx Pharmaceuticals Hold Rating: Navigating Setbacks with a Strategic Pivot and Long-Term Potential
Apr 04
3:15pm ET
Amylyx Pharmaceuticals: Hold Rating Maintained Amidst Drug Discontinuation and Pipeline Developments
Apr 04
7:22am ET
Amylyx Pharmaceuticals Enacts Major Restructuring and Refocuses Strategy
Apr 04
7:05am ET
Amylyx will reduce workforce by 70%
Apr 04
7:05am ET
Amylyx announces formal intention to remove RELYVRIO/ALBRIOZA from market
Mar 29
4:25am ET
Impact of Clinical Setbacks on Amylyx Pharmaceuticals: A Hold Rating Amidst Market Uncertainty
Mar 27
4:15pm ET
Amylyx Pharmaceuticals: Hold Rating Maintained Amidst Development Shifts and Trial Setbacks
Mar 22
3:37am ET
Class Action against Amylyx Pharmaceuticals Inc. (AMLX)
Mar 19
9:40am ET
Unusually active option classes on open March 19th
Mar 17
3:55pm ET
Maintaining Hold on Amylyx Pharmaceuticals Post-PHOENIX Study Setback and Relyvrio Uncertainties
Mar 17
3:41pm ET
Amylyx downgraded to Neutral from Buy at Mizuho
Mar 14
9:33am ET
Amylyx Pharmaceuticals Appoints New Board Member for 2025 Term
Mar 12
6:10am ET
Amylyx price target lowered to $8 from $42 at H.C. Wainwright
Mar 11
9:57am ET
Disney initiated, Foot Locker upgraded: Wall Street’s top analyst calls
Mar 11
6:37am ET
Baird downgrades Amylyx, sees Relyvrio being withdrawn soon
Mar 11
6:18am ET
Amylyx downgraded to Market Perform from Outperform at Leerink
Mar 11
5:07am ET
Amylyx downgraded to Neutral from Outperform at Baird
Mar 11
4:37am ET
Amylyx selloff on study miss overdone, says Deutsche Bank
Mar 11
12:55am ET
Evaluating Amylyx Pharmaceuticals: A Buy Rating Amidst PHOENIX Study Anticipation
Mar 08
1:45pm ET
Amylyx downgraded to Neutral from Buy at Goldman Sachs
Mar 08
1:45pm ET
Hold Rating on Amylyx Pharmaceuticals Amid Relyvrio Trial Setbacks and Revenue Uncertainty
Mar 08
11:30am ET
Amylyx Pharmaceuticals trading resumes
Mar 08
11:25am ET
Amylyx Pharmaceuticals trading halted, volatility trading pause
Mar 08
9:39am ET
Amylyx drops 85% after ALS trial did not meet primary endpoint
Mar 08
9:29am ET
Amylyx reports PHOENIX ALS trial did not meet primary endpoint
Apr 09
5:32pm ET
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
Apr 09
12:45pm ET
April 9, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AMLX
Apr 09
11:00am ET
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX
Apr 09
7:30am ET
Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline
Apr 09
7:00am ET
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Apr 09
5:00am ET
Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Apr 08
7:00pm ET
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX
Apr 08
5:51pm ET
AMLX FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action
Apr 08
1:10pm ET
48 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
Apr 08
11:45am ET
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX
Apr 08
10:45am ET
Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline
Apr 08
7:30am ET
Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline
Apr 08
7:00am ET
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Apr 08
4:40am ET
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX
Apr 07
6:00pm ET
AMLX FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
Apr 07
7:46am ET
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
Apr 06
5:40pm ET
AMLX FINAL DEADLINE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
Apr 06
9:16am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - AMLX
Apr 06
7:33am ET
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
Apr 05
5:39pm ET
AMLX FINAL DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
Apr 05
11:18am ET
Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint - Hagens Berman
Apr 05
8:08am ET
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX) as Company Formally Pulls Relyvrio from the Market
Apr 03
6:00pm ET
AMLX DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
Apr 02
5:59pm ET
AMLX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
Apr 02
5:43pm ET
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
Apr 02
4:04pm ET
AMLX 1-WEEK DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action
Apr 01
5:32pm ET
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
Apr 01
4:11pm ET
AMLX DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
Mar 30
9:08pm ET
TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
Mar 30
8:47am ET
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
Mar 29
9:08pm ET
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
AMLX Financials
Key terms
Ad Feedback
AMLX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AMLX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range